AXIM Biotechnologies, Inc.

AI-generated fair value estimate for this company.

Method: Net asset value/liquidation approach: cash and equivalents of $6,044 minus total debt/liabilities of ~$6.78M yields negative net tangible assets (approximately -$6.77M); with 363.13M shares outstanding and negative equity, per-share equity value floors at $0.00 under limited liability.

Reasoning: Axim Biotechnologies is functionally insolvent (Altman Z-score -32, Piotroski F-score 2, negative book value per share of -$0.03) with trivial LTM revenue of only $92,898 and a $4.14M net loss, making DCF/earnings multiples meaningless; NAV is the only defensible method and it implies effectively zero equity value, consistent with its $0.00362 share price and $1.31M total market cap.